No Data
No Data
Express News | Tourmaline Bio Inc: Topline Data Anticipated in First Half of 2025
Express News | Tourmaline Bio Initiates Clinical Development of Tour006 for Cardiovascular Diseases With First Patient Dosed in Phase 2 Tranquility Trial
Truist Financial Reaffirms Their Buy Rating on Tourmaline Bio (TRML)
Express News | HC Wainwright & Co. Reiterates Buy on Tourmaline Bio, Maintains $48 Price Target
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Tourmaline Bio (TRML)
Tourmaline Bio | 10-Q: Quarterly report
No Data